BOSTON--(BUSINESS WIRE)--At the SLAS2024 International Conference and Exhibition, Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument. The SPR #64 system has been engineered from the bottom up to accelerate drug discovery with increased SPR throughput, leading sensitivity and data quality. In modern drug discovery, SPR is indispensable for the real-time, label-free biophysical characterization of molecular interactions. ...

Bruker Corporation (BRKR) recently entered into a definitive agreement to acquire a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions, Chemspeed Technologies AG. This marks a significant stride into the realm of lab automation, digitalization, and scientific software solutions.This strategic move positions Bruker to further strengthen its Project Accelerate 2.0 initiative, which is focused on “Assays, Software, and Aftermarket.”Accelerating Entry Into AutomationChemspeed T ...

BASEL, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. The Chemspeed acquisition accelerates Bruker’s entry into lab automation, digitalizatio ...

ZURICH & NEWTON, Massachusetts--(BUSINESS WIRE)--Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the operational readiness of its new proteomics facility in Massachusetts. This US expansion facilitates access to select proteomics contract research organization (CRO) services for our US biopharma customers. The Massachusetts facility will initially focus on TrueDiscovery® data-independent acquisition (DIA) discovery proteomics services that o ...

Bruker Corporation (BRKR) is likely to grow in the coming quarters due to the solid prospects of the Bruker Scientific Instruments (“BSI”) Nano and BioSpin group. The addition of PhenomeX complements the Bruker cellular and sub-cellular analysis tools and brings opportunities for commercial synergies.However, BRKR’s operations are subject to intense competition from its peers in the industry.In the past year, this Zacks Rank #3 (Hold) stock has increased 5% against the 14.2% fall of the industry and a 22.6% ...

Bruker Corporation (NASDAQ:BRKR) 42nd Annual J.P. Morgan Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Frank Laukien - President and Chief Executive Officer Gerald Herman - Executive Vice President and Chief Financial Officer Mark Munch - President, Bruker Nano Group and Corporate Executive Vice President Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal This is Rachel Vatnsdal from the life science tools and diagnostics team at JPMorgan. Pleased to introduce ...

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY (in millions, except share data) | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------|-------|-------------------------|----------------------|------------| | Cash flows from operating activities: | | Nine September \n2023 | Months Ended 30, | 2022 | | Consolidated net income | $ | 223.9 | $ | 200.2 | | Adjus ...

(1)All in constant currency, and in comparison to the nine months ended September 30, 2022 Q3 2023 Earnings Presentation November 2, 2023 Introducing Bruker Cellular Analysis, a Leader in Single-Cell Biology Tools Complements Bruker's spatial biology and single-cell research tools via acquisition of PhenomeX Beacon® Optofluidic Systems (former Berkeley Lights) IsoSpark® System (former IsoPlexis) Strategic Rationale ✓ Technologies unique, highly valued by customers ✓ Expands footprint in translational, clini ...

Financial Data and Key Metrics Changes - Bruker reported a revenue increase of 16.3% year-over-year for Q3 2023, reaching $742.8 million, with organic revenue growth of 10.9% [20][26][119] - Non-GAAP EPS for Q3 2023 was $0.74, up 12.1% from $0.66 in Q3 2022, with a favorable tax rate offsetting foreign exchange headwinds [12][111] - For the first nine months of 2023, revenues increased by 15.8% to $2.11 billion, with organic revenue growth of 13.9% [5][102] Business Line Data and Key Metrics Changes - The BioSpin segment saw high single-digit organic revenue growth in Q3 2023, with revenue of $541 million for the first nine months [11][112] - Bruker Nano revenue grew in the low-20s percentage range, driven by strong performance in industrial semiconductor metrology and academic markets [113][101] - The CALID Group had revenue of $703 million for the first nine months, with growth in the high-teens percentage, particularly in life science mass spectrometry [96][101] Market Data and Key Metrics Changes - Americas revenue grew in the low single-digit percentage, while Asia-Pacific revenue grew in the teens percentage range, and European revenue had low-teens percentage growth year-over-year [27] - The EMEA region experienced mid-20% revenue growth year-over-year in Q3 2023 [27] - The backlog at the end of Q3 2023 remains strong, with expectations of continued elevated levels into 2024 [50][106] Company Strategy and Development Direction - Bruker is focused on its Project Accelerate 2.0 initiative, which aims to enhance innovation and operational excellence [4][94] - The acquisition of PhenomeX is expected to expand Bruker's capabilities in single-cell biology and complement existing product lines [8][24] - The company anticipates solid organic growth in 2024 and reaffirms its medium-term targets for 2026 [120] Management's Comments on Operating Environment and Future Outlook - Management acknowledged demand weakness in certain areas, such as COVID testing and biopharma, but remains optimistic about growth in scientific instruments and life science solutions [4][54] - The company expects to maintain a book-to-bill ratio around 1 for the year, despite some weakness in China and Japan [50][122] - Management confirmed that while there are challenges in the biopharma sector, Bruker's diversified portfolio positions it well for continued growth [54][55] Other Important Information - Bruker generated $144.6 million of operating cash flow in the first nine months of 2023, up about $42 million from the previous year [28] - The company expects non-GAAP EPS for fiscal year 2023 to be in the range of $2.48 to $2.53, reflecting a slight dilution from the Cellular Analysis business [29][44] Q&A Session Summary Question: What is the outlook for backlog and its impact on growth? - Management indicated that backlog remains elevated and will contribute to organic growth over the medium term, with expectations of a multi-year story [57][106] Question: How is the integration of PhenomeX progressing? - The integration is being accelerated, focusing on optimizing costs and streamlining operations, with significant annualized cost reductions expected [66][78] Question: What are the dynamics in the biopharma market? - Management confirmed a slowdown in biopharma investments, particularly among emerging companies, but noted that Bruker has a diversified portfolio to mitigate risks [54][55] Question: How is pricing sensitivity affecting orders? - Management stated that pricing power remains solid, with no significant changes in customer behavior regarding price sensitivity observed [70][72] Question: What is the expected impact of the new product launches on sales? - The introduction of new products like the timsTOF Ultra is expected to enhance competitiveness, although there may be short-term reevaluation by customers [88][120]

Bruker Corporation (NASDAQ:BRKR) Morgan Stanley 21st Annual Global Healthcare Conference Call September 13, 2023 4:14 PM ET Company Participants Gerald Herman - Executive Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant All right. Good afternoon, everyone. I’m Tejas Savant, and I’m the life sciences analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at mo ...